Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Bacteria develop resistance from rivals - study
The overuse of antibiotics may not be exclusively responsible for antibiotic resistance.

Research works to tackle antibiotic resistance

The overuse of antibiotics may not be exclusively responsible for antibiotic resistance, according to new research.

The study by the University of Basel found that bacteria can develop resistance to antibiotics from their competitors.
Writing in Cell Reports, researchers show that some bacteria inject a toxic cocktail into their rivals leading to cell lysis and death.

Researchers also found that if the released material contains certain drug-resistant genes, the specific resistance can be bestowed upon the new owner. As such, the antibiotic is no longer effective and the bacteria can reproduce.

“Some of these toxic proteins kill the bacterial competition very effectively, but do not destroy the cells,” explained Professor Marek Basler, who led the research. “Others severely damage the cell envelope, which leads to less of the attacked bacteria and hence the release of its genetic material.”

In the study, the researchers analysed the drug-resistant bacterium Acinetobacter baumanni - a typical hospital germ that originated during the Iraq war. The bacteria is also known as the ‘Iraq bug’ because it was spread by American soldiers returning home from combat.

The team found that the emergence and spread of multidrug resistance could be attributed - amongst other things - to the skills of certain bacteria. First, the bacteria combat their rivals by injecting them with toxic proteins - or effectors - using the type VI secretion system (T6SS), a poison syringe. Second, they are able to uptake and reuse the released genetic material.

In the model Acinetobacter baylyi, a close relative of the Iraq bug, Professor Basler’s team identified five differently acting toxic effectors.

“For the bacteria it makes absolute sense to produce not only a single toxin, but a cocktail of various toxins with different effects,” Basler explains. “This increases the likelihood that the rival can be successful and in some cases also lysed to release their DNA.”

Professor Basler added that the T6SS 'can also be found in other pathogens such as those which cause pneumonia or cholera'.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.